Western blot analysis of extracts from NK-92 cells, serum-starved overnight and untreated (-) or treated with Human Interleukin-2 (hIL-2) #8907 (10 ng/ml, 15 min; +), either with or without Tyrphostin AG-490 pretreatment (1 hr) at the indicated concentrations, using Phospho-Jak3 (Tyr980/981) (D44E3) Rabbit mAb #5031, Jak3 (D1H3) Rabbit mAb #8827, Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145, Stat3 (79D7) Rabbit mAb #4904, and β-Actin (D6A8) Rabbit mAb #8457.Learn more about how we get our images
Chemical structure of tyrphostin AG490Learn more about how we get our images
Tyrphostin AG-490 is supplied as a lyophilized powder. For a 50 mM stock, reconstitute the 10 mg in 679.58 μl DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 10-100 μM for 1-24 hr.
Store lyophilized or in solution at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Tyrphostin AG-490 is a membrane soluble protein tyrosine kinase inhibitor that primarily blocks Jak2 (IC50 = 10 μM) and Jak3 (IC50 = 20 μM) kinases (1,2). Research studies demonstrate that tyrphostin AG-490 inhibits proliferation and expansion of T cells (3). Unlike many other kinase inhibitors, tyrphostin AG-490 does not block a number of lymphocytic tyrosine kinases, such as Lck, Lyn, Btk, Syk, Jak1, Tyk2, or Src kinase (1,4). Additional studies indicate that tyrphostin AG-490 also selectively inhibits the EGFR (IC50 = 2 μM) and ErbB2 (IC50 = 13.5 μM) receptor tyrosine kinases (5).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. XP is a registered trademark of Cell Signaling Technology, Inc.